摘要
目的观察孟鲁司特钠联合沙美特罗替卡松粉吸入剂(50μg/500μg)(商品名:舒利迭)对老年慢性阻塞性肺疾病急性加重期(AECOPD)的治疗效果。方法 112例老年AECOPD患者,随机分为孟鲁司特钠联合舒利迭治疗组56例,对照组56例。治疗14 d后,评价所有患者的运动耐力、6 min步行距离、痰量、血气分析与肺功能指标第1秒用力呼气容积(FEV1.)、第1秒用力呼气容积占用力肺活量之比(FEV1/FVC)。结果对照组与治疗组上述指标均较治疗前改善(P<0.05与P<0.01),但治疗组较对照组改善更为明显(P<O.O5),且药物治疗安全性好。结论孟鲁司特钠联合舒利迭治疗老年AECOPD,疗效显著,能降低运动耐力评分、增加6 min步行距离、减少痰量、改善血气分析、促进患者肺功能的恢复。
Objective To investigate the clinical efficacy of montelukast in combination with seretide in the treatment of elderly patients with AECOPD. Methods A total of 112 elderly patients with AECOPD were randomly divided into two groups ：montelukast in combination with seretide group （n=56）,control group （n=56）.Endurance ratings,6 minutes walking distance, amount of expectoration,blood gas analysis and parameters of pulmonary function（FEV1, FEV1/FVC）of all patients were assessed after 14 days＇treatment. Results Compared with prior treatment, all indicators above of the two group improved a lot（P〈0.05 ,P〈0.01）,but treatment group was even more apparent than control group （P〈0.05）and with a sustained safety. Conclusion Combined montelukast and seretide has a significant effect on the treatment of el- derly patients with AECOPD by decreasing endurance ratings,increasing 6 minutes walking distance,reducing the amount of expectoration, improving blood gas analysis and promoting the recovery of pulmonary function.
出处
《中国现代医生》
2014年第16期51-53,57,共4页
China Modern Doctor
关键词
慢性阻塞性肺疾病
孟鲁司特钠
舒利迭
Chronic obstructive pulmonary disease（COPD）
Montelukas
Seretide
